Title: Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial
Authors: Millot, F ×
Suciu, S
Philippe, N
Benoit, Y
Mazingue, F
Uyttebroeck, A
Lutz, P
Mechinaud, F
Robert, A
Boutard, P
Marguerite, G
Ferster, A
Plouvier, E
Rialland, X
Behard, C
Plantaz, D
Dresse, M F
Philippet, P
Norton, L
Thyss, A
Dastugue, N
Waterkeyn, Catherine
Vilmer, E
Otten, J
Children's Leukemia Cooperative Group of the European Organiztaion for Research and Treatment of Cancer #
Issue Date: Apr-2001
Publisher: Grune & Stratton
Series Title: Journal of Clinical Oncology vol:19 issue:7 pages:1935-42
Abstract: The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.
ISSN: 0732-183X
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Non-KU Leuven Association publications
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science